|
|
||||||||
T DBH gene variant is not associated with epilepsy or antiepileptic drug response
From the Departments of Molecular Neurosciences (Drs. Depondt, Healy, and Wood) and Clinical and Experimental Epilepsy (Drs. Cock and Sisodiya), Institute of Neurology, and the Department of Biology (M.W. Burley and Dr. Goldstein), UCL, London, UK; and the Department of Human Genetics (Dr. Weinshenker), Emory University, Atlanta, GA.
Address correspondence and reprint requests to Dr. S.M. Sisodiya, Department of Clinical and Experimental Epilepsy, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; e-mail: s.sisodiya{at}ion.ucl.ac.uk
Dopamine ß-hydroxylase (DBH) catalyzes the conversion of dopamine to norepinephrine (NE). Animal studies show that genes in the NE pathway are candidates for susceptibility to epilepsy and antiepileptic drug (AED) response. The authors genotyped the 1021C
T major functional polymorphism in the DBH gene in 675 patients with epilepsy and 1,087 controls. The authors found no association with epilepsy, several epilepsy subtypes, or AED response. The results suggest that the 1021C
T variant does not contribute to epilepsy.
Received March 16, 2004. Accepted in final form June 17, 2004.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the October 26 issue to find the title link for this article.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |